FindTrial
Sign In

Exemestane 25 MG

DRUG7 trials

Sponsors

Chinese Academy of Medical Sciences, Instituto Nacional de Cancer, Brazil, H. Lee Moffitt Cancer Center and Research Institute, Irada Ibrahim-zada, European Organisation for Research and Treatment of Cancer - EORTC

Conditions

Breast CancerBreast Cancer MetastaticBreast CarcinomaBreast NeoplasmER-positive Breast CancerHER2-negative Breast CancerHepatocellular Carcinoma (HCC)Hormone Receptor Positive Tumor

Phase 1

Sapu003 in Advanced mTOR-sensitive Solid Tumors
RecruitingNCT07369505
SAPU NANO (US) LLCBreast Cancer Metastatic, Hepatocellular Carcinoma (HCC), Neuroendocrine Tumors +2
Start: 2025-12-15End: 2026-12-01Target: 27Updated: 2026-01-27

Phase 2

Fulvestrant 500mg With Exemestane Endocrine Therapy for Postmenopausal Advanced Breast Cancer Patients
NCT02646735
Chinese Academy of Medical SciencesBreast Cancer
Start: 2015-12-31End: 2020-12-31Target: 148Updated: 2017-01-02
A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer
NCT03024580
Instituto Nacional de Cancer, BrazilBreast Neoplasm
Start: 2017-03-06End: 2020-09-30Target: 20Updated: 2019-08-15
Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer
TerminatedNCT03874325
H. Lee Moffitt Cancer Center and Research InstituteBreast Cancer, Hormone Receptor Positive Tumor
Start: 2019-04-26End: 2021-01-06Updated: 2022-05-31
Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer
Active, not recruitingNCT05150652
Irada Ibrahim-zadaBreast Cancer, Breast Carcinoma, HER2-negative Breast Cancer +1
Start: 2022-02-18End: 2026-06-09Updated: 2026-01-07
Low Dose Exemestane vs Low Dose Tamoxifen in Post-menopausal Women at High Risk for Breast Cancer.
RecruitingNCT06364267
Andrea DeCensiBreast Cancer
Start: 2025-10-01End: 2027-01-31Target: 140Updated: 2025-11-18

Phase 3

Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)
RecruitingNCT05512364
European Organisation for Research and Treatment of Cancer - EORTCER-positive Breast Cancer, HER2-negative Breast Cancer, Stage IIB Breast Cancer +1
Start: 2023-12-15End: 2035-11-01Target: 220Updated: 2025-08-19

Related Papers

Neoadjuvant therapy with an aromatase inhibitor and durvalumab in postmenopausal patients with hormone receptor-positive breast cancer.
2026-02-16
EORTC-2129-BCG: Elacestrant for treating ER+/HER2- breast cancer patients with ctDNA relapse (TREAT ctDNA).
Journal of Clinical Oncology2025-05-281 citations
heredERA Breast Cancer: a phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancer
BMC Cancer2024-05-246 citations
36P Megestrol acetate resistance in estrogen receptor-positive advanced breast cancer in the MEGA trial
ESMO Open2023-05-01
Clinical efficacy of fulvestrant versus exemestane as first-line therapies for Chinese postmenopausal oestrogen-receptor positive /human epidermal growth factor receptor 2 -advanced breast cancer (FRIEND study)
European Journal of Cancer2023-02-1511 citations